|
| 36208017 | Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel. | Cancer Med | 2023 |
| 36208017 | Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel. | Cancer Med | 2023 |
| 36450266 | Analysis of Lymph Node Metastasis and Risk Factors in 975 Patients with FIGO 2009 Stage IA-IIA Cervical Cancer. | Gynecol Obstet Invest | 2023 |
| 37501016 | Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. | Nat Med | 2023 |
| 37501016 | Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. | Nat Med | 2023 |
| 36450266 | Analysis of Lymph Node Metastasis and Risk Factors in 975 Patients with FIGO 2009 Stage IA-IIA Cervical Cancer. | Gynecol Obstet Invest | 2023 |
| 34399990 | LINC00882 Plays a Tumor-promoter Role in Colorectal Cancer by Targeting miR-3619-5p to Up-regulate CTNNB1. | Arch Med Res | 2022 |
| 35523008 | Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. | Transl Oncol | 2022 |
| 35281860 | Low expression of FOXP2 predicts poor survival and targets caspase-1 to inhibit cell pyroptosis in colorectal cancer. | J Cancer | 2022 |
| 34399990 | LINC00882 Plays a Tumor-promoter Role in Colorectal Cancer by Targeting miR-3619-5p to Up-regulate CTNNB1. | Arch Med Res | 2022 |
| 35031545 | Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. | Clin Cancer Res | 2022 |
| 34967707 | Cucurbitacin B regulates lung cancer cell proliferation and apoptosis <i>via</i> inhibiting the IL-6/STAT3 pathway through the lncRNA XIST/miR-let-7c axis. | Pharm Biol | 2022 |
| 35523008 | Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. | Transl Oncol | 2022 |
| 35281860 | Low expression of FOXP2 predicts poor survival and targets caspase-1 to inhibit cell pyroptosis in colorectal cancer. | J Cancer | 2022 |
| 35031545 | Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. | Clin Cancer Res | 2022 |
| 34967707 | Cucurbitacin B regulates lung cancer cell proliferation and apoptosis <i>via</i> inhibiting the IL-6/STAT3 pathway through the lncRNA XIST/miR-let-7c axis. | Pharm Biol | 2022 |
| 32976576 | A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. | Blood | 2021 |
| 34149932 | Pentraxin-3 inhibits milky spots metastasis of gastric cancer by inhibiting M2 macrophage polarization. | J Cancer | 2021 |
| 32976576 | A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. | Blood | 2021 |
| 34663329 | Upregulation of SNTB1 correlates with poor prognosis and promotes cell growth by negative regulating PKN2 in colorectal cancer. | Cancer Cell Int | 2021 |
| 34533429 | Exosomal miR-132-3p from mesenchymal stem cells alleviated LPS-induced acute lung injury by repressing TRAF6. | Autoimmunity | 2021 |
| 34530563 | [Da Vinci robot-assisted pylorus and vagus nerve-preserving partial gastrectomy for gastric cancer]. | Zhonghua Wei Chang Wai Ke Za Zhi | 2021 |
| 34530563 | [Da Vinci robot-assisted pylorus and vagus nerve-preserving partial gastrectomy for gastric cancer]. | Zhonghua Wei Chang Wai Ke Za Zhi | 2021 |
| 34663329 | Upregulation of SNTB1 correlates with poor prognosis and promotes cell growth by negative regulating PKN2 in colorectal cancer. | Cancer Cell Int | 2021 |
| 34533429 | Exosomal miR-132-3p from mesenchymal stem cells alleviated LPS-induced acute lung injury by repressing TRAF6. | Autoimmunity | 2021 |
| 34149932 | Pentraxin-3 inhibits milky spots metastasis of gastric cancer by inhibiting M2 macrophage polarization. | J Cancer | 2021 |
| 31425872 | Efficacy of Celiac Branch Preservation in Billroth-â¿ Reconstruction After Laparoscopy-Assisted Distal Gastrectomy. | J Surg Res | 2020 |
| 32194791 | Cytokine TNF-α promotes invasion and metastasis of gastric cancer by down-regulating Pentraxin3. | J Cancer | 2020 |
| 31903638 | Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. | Am J Hematol | 2020 |
| 32645282 | Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. | Lancet Oncol | 2020 |
| 32747013 | Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. | Gynecol Oncol | 2020 |
| 31425872 | Efficacy of Celiac Branch Preservation in Billroth-â¿ Reconstruction After Laparoscopy-Assisted Distal Gastrectomy. | J Surg Res | 2020 |
| 31903638 | Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. | Am J Hematol | 2020 |
| 32747013 | Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. | Gynecol Oncol | 2020 |
| 32645282 | Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. | Lancet Oncol | 2020 |
| 32194791 | Cytokine TNF-α promotes invasion and metastasis of gastric cancer by down-regulating Pentraxin3. | J Cancer | 2020 |
| 30297515 | Relationship between Circulating Inflammation Proteins and Lung Cancer Diagnosis in the National Lung Screening Trial. | Cancer Epidemiol Biomarkers Prev | 2019 |
| 30297515 | Relationship between Circulating Inflammation Proteins and Lung Cancer Diagnosis in the National Lung Screening Trial. | Cancer Epidemiol Biomarkers Prev | 2019 |
| 30953795 | Circulating Inflammation Proteins Associated With Lung Cancer in African Americans. | J Thorac Oncol | 2019 |
| 31345267 | A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. | J Immunother Cancer | 2019 |
| 31345267 | A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. | J Immunother Cancer | 2019 |
| 30953795 | Circulating Inflammation Proteins Associated With Lung Cancer in African Americans. | J Thorac Oncol | 2019 |
| 29298798 | Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. | Clin Cancer Res | 2018 |
| 30370398 | Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. | J Appl Lab Med | 2018 |
| 30370397 | Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. | JCO Precis Oncol | 2018 |
| 29298798 | Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. | Clin Cancer Res | 2018 |
| 30370398 | Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. | J Appl Lab Med | 2018 |
| 30370397 | Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. | JCO Precis Oncol | 2018 |
| 27328856 | A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. | Clin Genitourin Cancer | 2017 |
| 28465443 | Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. | Clin Cancer Res | 2017 |